SCHEMBL5539485

SCHEMBL5539485

CN(C[C@](C)(O)Cn1cc([N+](=O)[O-])nc1Cl)C1CCN(c2ccc(Cl)cc2)CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.38
LSS P48449 2/20 0.37
NOS3 P29474 1/20 0.37
NOS1 P29475 1/20 0.37
NOS2 P35228 1/20 0.37
LMNA P02545 1/20 0.35
F10 P00742 3/20 0.35
NPY5R Q15761 1/20 0.34
ENPP2 Q13822 1/20 0.34
PTGS1 P23219 1/20 0.33
SLC6A2 P23975 1/20 0.33
SLC6A4 P31645 1/20 0.33
CHIT1 Q13231 2/20 0.33
CHIA Q9BZP6 2/20 0.33
KCNH2 Q12809 1/20 0.33
CYP3A4 P08684 1/20 0.33
MAPT P10636 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
NPBWR1 P48145 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5539491 1.00 KMT2A (0.38) KMT2ALSSNOS3NOS1NOS2
SCHEMBL5535348 0.92 SERPINE1 (0.38) KMT2ALMNAENPP2PTGS1SLC6A2
SCHEMBL5535342 0.92 SERPINE1 (0.38) KMT2ALMNAENPP2PTGS1SLC6A2
SCHEMBL5540765 0.91 CYP3A4 (0.34) KMT2ALMNAPTGS1SLC6A2SLC6A4
SCHEMBL5540771 0.91 CYP3A4 (0.34) KMT2ALMNAPTGS1SLC6A2SLC6A4
SCHEMBL5536827 0.89 PTGS1 (0.46) PTGS1SLC6A2SLC6A4KCNH2CYP3A4
SCHEMBL5536822 0.89 PTGS1 (0.46) PTGS1SLC6A2SLC6A4KCNH2CYP3A4
SCHEMBL5535657 0.82 KMT2A (0.42) KMT2ALMNAENPP2MAPTSMN1; SMN2
SCHEMBL5535653 0.82 KMT2A (0.42) KMT2ALMNAENPP2MAPTSMN1; SMN2
SCHEMBL5540109 0.81 NR1D1 (0.40) KMT2ALMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 KMT2A 4267/4885LSS 2164/4885NOS3 214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.